1. Introduction {#sec1-molecules-24-04191}
===============

Nowadays, cancer has a serious impact on human health with a high mortality rate \[[@B1-molecules-24-04191]\]. The rapid development of drug resistance and the acute side effects of clinical used anticancer drugs are still the major obstacles to effective chemotherapy \[[@B2-molecules-24-04191],[@B3-molecules-24-04191]\]. Therefore, the discovery and development of new drugs and therapies with high efficacy and low side effects is always the basic mission for medicinal chemists. Natural products have played a dominant role in drug discovery, according to their chemically structural diversity, good biological activities and biocompatibility. There has been increased interest in the search of antitumor drugs from natural sources, and many natural or natural based antitumor drugs such as vinblastine, etoposide and paclitaxel were found and clinically used in recent years \[[@B4-molecules-24-04191]\].

Abietanes are a family of natural tricyclic diterpenoids with interesting pharmacological activity including antitumor, antimicrobial, antiviral, antiulcer, and anti-inflammatory activities \[[@B5-molecules-24-04191],[@B6-molecules-24-04191],[@B7-molecules-24-04191],[@B8-molecules-24-04191],[@B9-molecules-24-04191]\]. Interestingly, dehydroabietic acid (DHAA) and its derivatives have exhibited a broad spectrum of biological activities including antibacterial \[[@B10-molecules-24-04191],[@B11-molecules-24-04191],[@B12-molecules-24-04191],[@B13-molecules-24-04191]\], antifungal \[[@B14-molecules-24-04191]\], antiprotozoal \[[@B15-molecules-24-04191]\], antiviral \[[@B16-molecules-24-04191]\], antiulcer \[[@B17-molecules-24-04191]\], antiherpetic \[[@B18-molecules-24-04191]\] and anti-aging \[[@B19-molecules-24-04191]\]. Especially, a number of DHAA derivatives have been reported in recent years which showed significant antitumor property through DNA binding, apoptosis or oncosis inducing mechanisms \[[@B20-molecules-24-04191],[@B21-molecules-24-04191],[@B22-molecules-24-04191]\]. Hence, a significant amount of attention has been diverted towards the structural modification of dehydroabietic acid to develop new anticancer agents.

On the other hand, 1,2,3-triazole, a privileged building block in the discovery of new anticancer agents, plays a key role in enhancing the cytotoxicity towards the cancer cells because of its improved solubility, cell permeability and pharmacokinetic parameters at the binding site \[[@B23-molecules-24-04191],[@B24-molecules-24-04191]\]. It has been reported that hybridization of 1,2,3-triazole framework other anticancer pharmacophores has the potential to provide novel anticancer candidates \[[@B25-molecules-24-04191],[@B26-molecules-24-04191],[@B27-molecules-24-04191],[@B28-molecules-24-04191]\]. Moreover, some of 1,2,3-triazole containing compounds such as Cefatrizine and Carboxyamidotriazole have already been applied in clinics or under clinical trials for fighting against cancers. Click chemistry is considered to be a nearly perfect synthesizing strategy for reaction between azides and alkynes to afford 1,2,3-triazoles under mild conditions. Therefore, it has been widely applied in many aspects of drug discovery, ranging from the design of lead compounds to tagging of biological systems \[[@B29-molecules-24-04191],[@B30-molecules-24-04191]\].

Considering the above benefits and in continuation of our interest in searching for the pharmacological effects of terpenoid derivatives \[[@B31-molecules-24-04191],[@B32-molecules-24-04191],[@B33-molecules-24-04191],[@B34-molecules-24-04191]\]. We envisioned that the combination of the DHAA framework with 1,2,3-triazole unit may afford the desired high-performance anticancer agents. In this study, a series of novel DHAA-1,2,3-triazole hybrids were synthesized and their cytotoxic activities were assessed in vitro against CNE-2 (Nasopharynx), HepG2 (liver), HeLa (epithelial cervical), and BEL-7402 (liver) human cancer cell lines and HL-7702 normal human liver cell line.

2. Results and Discussion {#sec2-molecules-24-04191}
=========================

2.1. Synthesis and Characterization {#sec2dot1-molecules-24-04191}
-----------------------------------

DHAA derivatives containing 1,2,3-triazole moiety were synthesized as presented in [Scheme 1](#molecules-24-04191-sch001){ref-type="scheme"}. All 16 compounds have been confirmed by FT-IR, ^1^H NMR, ^13^C NMR ESI-MS and elemental analysis. As illustrated in [Scheme 1](#molecules-24-04191-sch001){ref-type="scheme"}, DHAA was treated with propargyl bromide, anhydrous potassium carbonate in dimethylformamide (DMF) to fabricate a good yield of propynyl ester **2.** Huisgen \[3+2\] cycloaddition of **2** with benzyl chloride/bromide and sodium azide in the presence of cuprous iodide in a DMF aqueous solution resulted in the formation of 1,4 substituted-triazolyl derivatives **3a**--**p** by one-pot route.

The FT-IR spectra of the target compounds **3a**--**p** exhibited characteristic moderate absorption bands at about 1716 cm^−1^ attributed to the stretching vibrations of the C=O. The bands at 1600--1450 cm^−1^ were assigned to the vibration of the skeleton in benzene rings. The bands at 2950--2850 cm^−1^ were assigned to the stretching vibrations of the C-H in methyl or methylene. The ^1^H NMR spectra of the target compounds **3a**--**p** showed characteristic signals at about 7.5 ppm assigned to the triazole protons and signals at 8.30--6.80 ppm assigned to the benzene protons. The ^13^C NMR spectra of the target compounds **3a**--**p** showed peaks for C=O at about 178 ppm, and for aromatic rings at 160--113 ppm.

2.2. In Vitro Assay of Antiproliferative Activity {#sec2dot2-molecules-24-04191}
-------------------------------------------------

The antiproliferative activities of the 16 library members were tested against four human cancer cell lines including human nasopharyngeal carcinoma cell (CNE-2), human liver cancer cell (HepG2), human hepatocellular carcinoma cell (BEL-7402), human cervical cancer cells (HeLa), and human normal liver cell (HL-7702) using MTT assay according the reported literature method \[[@B35-molecules-24-04191]\]. The tested results were shown in [Table 1](#molecules-24-04191-t001){ref-type="table"}.

It was found from [Table 1](#molecules-24-04191-t001){ref-type="table"} that some of the newly synthesized compounds had significant antineoplastic activity against four tested cancer cell lines, indicating that the introduction of 1,2,3-triazole moiety on the DHAA skeleton increased anti-tumor activity. In particular, compounds **3c** and **3k** exhibited good antitumor activity against HepG2 with IC~50~ values of 5.90 ± 0.41 and 6.25 ± 0.37 μM, better than those of positive control cisplatin. Moreover, compounds **3c** (R = *m*-F), **3d** (R = *p*-F) and **3l** (R = *m*-NO~2~) against CNE-2 with IC~50~ values of 10.92 ± 0.21, 12.20 ± 0.33 and 11.45 ± 0.18 μM, respectively. However, compound **3d** and **3j** showed moderate activity active against BEL-7402 with IC~50~ values of 14.84 ± 075 and 14.53 ± 0.62 μM, respectively. These results declared that introduction of an electron withdrawing group was superior to an electron donating group on the benzene ring against CNE-2 (nasopharynx) cell line. The benzene ring that possessed an electron withdrawing group in *meta*-positions was better than in *ortho*- and *para*- positions. Compound **3b** exhibited the best antitumor activity against Hela (epithelial cervical) with values of 17.76 ± 0.31 μM. Most compounds showed more potent anticancer activities against the HepG2 tumor cells compared to the parent compound. It was important to note that compounds **3a**--**p** showed a certain selectivity against four tumor cell lines and low cytotoxicity on the human normal liver cell (HL-7702).

3. Experimental Section {#sec3-molecules-24-04191}
=======================

3.1. General Information {#sec3dot1-molecules-24-04191}
------------------------

All commercially available reagents including substituted benzyl chloride/bromide were purchased from Energy Chemicals and used without further purification. Optical rotations were measured on a WZZ-3 polarimeter in CH~2~Cl~2~ at 20 °C (Shanghai Shenguang Instrument, Co., Ltd., Shanghai, China). FT-IR spectra was recorded on a Prestige-21 spectrometer, and samples were prepared as KBr plates (Shimadzu, Co., Ltd., Tokyo, Japan). ^1^H NMR and ^13^C NMR spectra were obtained using a Bruker Avance 600/400 MHz spectrometer in CDCl~3~ with tetramethylsilane (TMS)as an internal standard (Brucker Co., Ltd., Zurich, Switzerland). Elemental analyses were carried out on a PE 2400II elemental analyzer (Perkin Elmer Instruments Co., Ltd., Waltham, MA, USA). Melting points were determined on WRX-4 digital melting point apparatus (uncorrected) (Shanghai YiCe Apparatus & Equipment, Co., Ltd., Shanghai, China). Mass spectra were carried out with a Shimazu liquid chromatograph mass spectrometer (Shimadzu, Co., Ltd., Tokyo, Japan). NMR and IR spectra of compounds **3** can be found in the [Supplementary Materials](#app1-molecules-24-04191){ref-type="app"}.

3.2. Synthesis of Dehydroabietic Acid Propynyl Ester ***2*** {#sec3dot2-molecules-24-04191}
------------------------------------------------------------

In a round bottom flask, anhydrous potassium carbonate (9.4 g) and propargyl bromide (2.8 mL) were added to a solution of compound **1** (9.3 g) in dry DMF (40 mL), and the reaction mixture was stirred at room temperature for 4 h. Reaction was monitored by TLC and the crude product was poured into ice water (200 mL), then the mixture was extracted with ethyl acetate (3 × 20 mL). The combined organic layer was washed with saturated salt water three times, dried over anhydrous sodium sulfate and purified through silica gel chromatography (petroleum ether-EtOAc = 20:1, *v*/*v*) to offer yellow liquid **2** in yield 86.3%; IR (KBr, cm^−1^) 3278 (stretching, m, C≡C-H), 2954, 2933, 2872 (stretching, s, aliphatic C-H), 2127 (stretching, w, C≡C), 1730 (stretching, s, C=O); ^1^H NMR (400 MHz, CDCl~3~): 7.09 (d, 1H, *J* = 8.2 Hz, H-11), 6.92 (dd, 1H, *J* = 8.2, 1.6 Hz, H-12), 6.81 (s, 1H, H-14), 4.59 (ddd, 2H, *J* = 39.7, 15.5, 2.4 Hz, H-22), 2.88 -- 2.70 (m, 3H, H-15 and H-7), 2.35 (t, 1H, *J* = 2.4 Hz, H-23), 2.26--2.17 (m, 2H, He-1 and H-5), 1.76 -- 1.34 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.22 (s, 3H, H-19), 1.16 (s, 3H, H-20), 1.14 (s, 6H, H-16 and H-17); ^13^C NMR (101 MHz, CDCl~3~) δ 177.70, 146.80, 145.77, 134.71, 126.90, 124.17, 123.94, 77.98, 74.43, 52.00, 47.67, 44.85, 37.96, 36.98, 36.37, 33.47, 30.00, 25.13, 23.96, 21.66, 18.55, 16.48.

3.3. General Procedure for the Synthesis of the Target Compounds ***3a**--**p*** {#sec3dot3-molecules-24-04191}
--------------------------------------------------------------------------------

A solution of benzyl chloride/bromide (40 mmol) and sodium azide (40 mmol) in *N*,*N*-dimethylformamide (DMF)/water (6 mL, 2:1) was stirred at room temperature. Subsequently, propynyl ester **2** (30 mmol) and CuI (0.002 g) were added, the reaction was performed for 5 h. Upon completion of the reaction, the crude mixture was poured into ice water (20 mL), extracted with CHCl~3~ (3 × 20 mL) and the solution was washed with saturated salt water, dried over Na~2~SO~4~. Purification was performed by chromatography on silica gel (petroleum ether-EtOAc = 5:1, *v*/*v*) to give the target compounds **3a**--**p**, which were characterized by means of FT-IR, ^1^H NMR, ^13^C NMR, ESI-MS and elemental analysis techniques.

*(1-benzyl-1H-1,2,3-triazole-4-yl)dehydroabietic acid methyl ester* (**3a**): White solid; yield 58.0%; m.p. 181.0--183.4 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+26.38 (c 0.012, CH~2~Cl~2~); IR (KBr, cm^−1^) 3126 (stretching, w, C=C-H), 2949, 2868 (stretching, s, aliphatic C-H), 1716 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.53 (s, 1H, H-23), 7.41 (m, 3H, H-26, H-28 and H-30), 7.30 (m, 2H, H-27 and H-29), 7.17 (d, 1H, *J* = 8.2 Hz, H-11), 7.02 (d, 1H, *J* = 8.1 Hz, H-12), 6.86(s, 1H, H-14), 5.56 (s, 2H, H-24), 5.22 (dd, 2H, *J* = 68.2, 12.7 Hz, H-21), 2.86--2.83 (m, 1H, H-15), 2.78\~2.65 (m, 2H, H-7), 2.30 (d, 1H, *J* = 12.6 Hz, He-1), 2.21 (dd,1H, *J* = 12.5 Hz, 1.8, H-5), 1.79--1.46 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.27 (s, 3H, H-19), 1.26 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.21 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.56, 146.87, 145.83, 143.70, 134.75, 129.30, 128.97, 128.19, 127.02, 124.30, 124.06, 123.67, 57.88, 54.32, 47.69, 44.93, 38.02, 37.04, 36.49, 33.59, 30.05, 25.29, 24.13, 24.12, 21.73, 18.64, 16.59; ESI-MS *m/z*: 470.88 (\[M − H\]^−^). Anal. Calcd for C~30~H~37~N~3~O~2~: C 76.40, H 7.91, N 8.91; found C 76.39, H 7.93, N 8.88.

*\[1-(2-fluorobenzyl)-1H-1,2,3-triazole-4-yl\]*dehydroabietic acid methyl ester (**3b**): White solid; yield 46.6%; m.p. 122.4--125.8 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+13.82 (c 0.016, CH~2~Cl~2~); IR (KBr, cm^−1^) 2943, 2866 (stretching, s, aliphatic C-H), 1718 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.63 (s, 1H, H-23), 7.40 (dd, 1H, *J* = 14.2, 6.8 Hz, H-27), 7.30 (t, 1H, *J* = 7.0 Hz, H-28), 7.21--7.13 (m, 3H, H-29, H-30, H-11), 7.02 (d, 1H, *J* = 8.1, H-12), 6.87 (s, 1H, H-14), 5.62 (s, 2H, H-24), 5.23 (dd, 2H, *J* = 68.3, 12.7 Hz, H-21), 2.85 (m, 1H, H-15), 2.79--2.69 (m, 2H, H-7), 2.31 (d, 1H, *J* = 13.1 Hz, He-1), 2.22 (dd, 1H, *J* = 12.4, 1.4 Hz, H-5), 1.90--1.67 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.28 (s, 3H, H-19), 1.26 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.21 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.54, 160.68, 146.88, 145.82, 143.68, 134.76, 131.13, 130.70, 127.03, 125.01, 124.31, 124.06, 123.86, 121.98, 116.01, 57.84, 47.85, 47.70, 44.94, 38.03, 37.05, 36.50, 33.60, 30.06, 25.30, 24.13, 21.75, 18.66, 16.61; ESI-MS *m/z*: 488.88 (\[M − H\]^−^). Anal. Calcd for C~30~H~36~FN~3~O~2~: C 73.59, H 7.41, N 8.58; found C 73.56, H 7.39, N 8.59.

*\[1-(3-fluorobenzyl)-1H-1,2,3-triazole-4-yl\]*dehydroabietic acid methyl ester (**3c**): White solid; yield 58.7%; m.p. 175.7--178.3 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+17.26 (c 0.014, CH~2~Cl~2~); IR (KBr, cm^−1^) 2919 (stretching, s, aliphatic C-H), 1712 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.58 (s, 1H, H-23), 7.38 (dd, 1H, *J* = 13.8, 8.0 Hz, H-29), 7.18 (d, 1H, *J* = 8.2 Hz, H-11), 7.09 (m,2H, H-26 and H-28), 7.02 (d, 1H, *J* = 8.2 Hz, H-12), 6.98 (d, 1H, *J* = 9.2 Hz, H-30), 6.87 (s, 1H, H-14), 5.56 (s, 2H, H-24), 5.24 (dd, 2H, *J* = 68.0, 12.7 Hz, H-21), 2.89\~2.81 (m, 1H, H-15), 2.79--2.66 (m, 2H, H-7), 2.31 (d, 1H, *J* = 12.5 Hz, He-1), 2.22 (dd, 1H, *J* = 12.5 Hz, 1.8, H-5), 1.84--1.46 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.28 (s, 3H, H-19), 1.26 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.21 (s, 3H, H-20); ^13^C NMR(150 MHz, CDCl~3~): δ 178.57, 163.15, 146.86, 145.86, 143.90, 137.08, 134.71, 130.96, 127.03, 124.30, 124.08, 123.82, 123.66, 116.00, 115.11, 58.82, 53.62, 47.70, 44.94, 38.03, 37.04, 36.51, 33.60, 30.05, 25.29, 24.12, 21.75, 18.64, 16.60; ESI-MS *m/z*: 488.95 (\[M − H\]^−^). Anal. Calcd for C~30~H~36~FN~3~O~2~: C 73.59, H 7.41, N 8.58; found C 73.59, H 7.38, N 8.57.

*\[1-(4-fluorobenzyl)-1H-1,2,3-triazole-4-yl\]*dehydroabietic acid methyl ester (**3d**): White solid; yield 55.4%; m.p. 183.0--186.3 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+22.92 (c 0.011, CH~2~Cl~2~); IR (KBr, cm^−1^) 2949 (stretching, s, aliphatic C-H), 1716 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.54(s, 1H, H-23), 7.30 (dd, 2H, *J* = 8.6, 5.2 Hz, H-26 and H-30), 7.18 (d, 1H, *J* = 8.2 Hz, H-11), 7.10 (t, 2H, *J* = 8.6 Hz, H-27 and H-29), 7.03 (d, 1H, *J* = 8.2 Hz, H-12), 6.87 (s, 1H, H-14), 5.53 (s, 2H, H-24), 5.23 (dd, 2H, *J* = 64.4, 12.7 Hz, H-21), 2.88--2.83 (m, 1H, H-15), 2.77--2.66 (m, 2H, H-7), 2.31 (d, 1H, *J* = 12.7 Hz, He-1), 2.21 (dd, 1H, *J* = 12.5 Hz, 1.8 Hz, H-5), 1.91--1.48 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.28 (s, 3H, H-19), 1.26 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.21 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.56, 163.02, 146.87, 145.89, 143.82, 134.69, 130.57, 130.10, 127.02, 124.31, 124.10, 123.59, 116.31, 57.86, 53.55, 47.70, 44.94, 38.02, 37.04, 36.50, 33.60, 30.06, 25.29, 24.12, 21.73, 18.64, 16.61; ESI-MS *m/z*: 488.81 (\[M − H\]^−^). Anal. Calcd for C~30~H~36~FN~3~O~2~: C 73.59, H 7.41, N 8.58; found C 73.60, H 7.38, N 8.56.

*\[1-(2-chlorobenzyl)-1H-1,2,3-triazole-4-yl\]*dehydroabietic acid methyl ester (**3e**): White solid; yield 60.4%; m.p. 80.6--84.3 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+12.69 (c 0.010, CH~2~Cl~2~); IR (KBr, cm^−1^) 2931 (stretching, s, aliphatic C-H)V, 1720 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.55 (s, 1H, H-23), 7.38--7.31 (m, 2H, H-28 and H-30), 7.27 (s, 1H, H-27), 7.16 (d, 2H, *J* = 8.2 Hz, H-11 and H-29), 7.00 (d, 1H, *J* = 8.1 Hz, H-12), 6.86 (s, 1H, H-14), 5.52 (s, 2H, H-24), 5.23 (dd, 2H, *J* = 64.3, 12.7 Hz, H-21), 2.84 (dt, 1H, *J* = 13.8, 6.9 Hz, H-15), 2.77\~2.65 (m, 2H, H-7), 2.29 (d, 1H, *J* = 12.6 Hz, He-1), 2.20 (dd, 1H, *J* = 12.5, 1.7 Hz, H-5), 1.82\~1.47 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.27 (s, 3H, H-19), 1.24 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.20 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.46, 146.73, 145.73, 143.82, 136.48, 135.09, 134.59, 130.46, 129.07, 128.06, 126.91, 126.06, 124.16, 123.94, 123.64, 57.70, 53.46, 47.57, 44.81, 37.90, 36.91, 36.38, 33.46, 29.90, 25.15, 23.99, 21.62, 18.51, 16.47; ESI-MS *m/z*: 529.00 (\[M + Na\]^+^). Anal. Calcd for C~30~H~36~ClN~3~O~2~: C 71.20, H 7.17, N 8.30; found C 71.16, H 7.15, N 8.29.

*\[1-(3-chlorobenzyl)-1H-1,2,3-triazole-4-yl\]*dehydroabietic acid methyl ester (**3f**): White solid; yield 52.3%; m.p. 153.2--155.5 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+27.86 (c 0.012, CH~2~Cl~2~); IR (KBr, cm^−1^) 2939 (stretching, s, aliphatic C-H), 1714 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.61 (s, 1H, H-23), 7.46 (dd, 1H, *J* = 8.0, 1.1 Hz, H-28), 7.34 (td, 1H, *J* = 7.7, 1.7 Hz, H-29), 7.29 (d, 1H, *J* = 9.0 Hz, H-26), 7.21 (dd, *J* = 7.6, 1.5 Hz, 1H, H-30), 7.16 (d, 1H, *J* = 8.2 Hz, H-11), 7.00 (dd, *J* = 8.1, 1.6 Hz, 1H, H-12), 6.86 (d, *J* = 12.8 Hz, 1H, H-14), 5.68 (s, 2H, H-24), 5.23 (dd, 2H, *J* = 68.2, 12.7 Hz, H-21), 2.84 (dt, 1H, *J* = 13.8, 6.9 Hz, H-15), 2.79--2.67 (m, 2H, H-7), 2.29 (d, 1H, *J* = 12.5 Hz, He-1), 2.21 (dd, *J* = 12.5, 1H, 2.0 Hz, H-5), 1.81\~1.47 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.27 (s, 3H, H-19), 1.24 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.20 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.40, 146.75, 145.70, 143.48, 134.61, 133.54, 132.36, 130.37, 130.32, 129.98, 127.62, 126.89, 124.16, 123.93, 123.86, 57.72, 51.45, 47.57, 44.79, 37.91, 36.92, 36.40, 33.46, 29.96, 25.15, 24.00, 23.98, 21.64, 18.53, 16.47; ESI-MS *m/z*: 506.00 (\[M\]^+^). Anal. Calcd for C~30~H~36~ClN~3~O~2~: C 71.20, H 7.17, N 8.30; found C 71.21, H 7.14, N 8.32.

*\[1-(4-chlorobenzyl)-1H-1,2,3-triazole-4-yl\]*dehydroabietic acid methyl ester (**3g**): White solid; yield 44.7%; m.p. 176.9--179.2 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+18.67 (c 0.015, CH~2~Cl~2~); IR (KBr, cm^−1^) 2926 (stretching, s, aliphatic C-H), 1718 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.52 (s, 1H, H-23), 7.37 (d, 2H, *J* = 8.4 Hz, H-27 and H-29), 7.23 (d, 2H, *J* = 8.4 Hz, H-26 and H-30), 7.17 (s, 1H, H-11), 7.01 (dd, 1H, *J* = 8.1, 1.4 Hz, H-12), 6.86 (s, 1H, H-14), 5.51 (s, 2H, H-24), 5.21 (dd, 2H, *J* = 61.7, 12.7 Hz, H-21), 2.84 (dt, 1H, *J* = 13.8, 6.9 Hz, H-15), 2.77--2.63 (m, 2H, H-7), 2.29 (d, 1H, *J* = 12.9 Hz, He-1), 2.19 (dd, 1H, *J* = 12.5, 1.9 Hz, H-5), 1.81\~1.47 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.26 (s, 3H, H-19), 1.24 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.20 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.44, 146.73, 145.77, 143.77, 134.92, 134.55, 133.04, 129.38, 126.90, 124.16, 123.95, 123.49, 77.25, 77.04, 76.83, 57.72, 53.43, 47.58, 44.81, 37.89, 36.91, 36.39, 33.47, 29.91, 25.15, 23.99, 21.61, 18.51, 16.47; ESI-MS *m/z*: 505.20 (\[M − H\]^−^). Anal. Calcd for C~30~H~36~ClN~3~O~2~: C 71.20, H 7.17, N 8.30; found C 71.19, H 7.18, N 8.27.

*\[1-(2-bromobenzyl)-1H-1,2,3-triazole-4-yl\]*dehydroabietic acid methyl ester (**3h**): White solid; yield 48.6%; m.p. 95.1--97.3 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+32.13 (c 0.014, CH~2~Cl~2~); IR (KBr, cm^−1^) 2929 (stretching, s, aliphatic C-H), 1714 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.67--7.61 (m, 2H, H-23 and H-27), 7.33 (t, 1H, *J* = 7.5 Hz, H-29), 7.26 (t, 1H, *J* = 7.7 Hz, H-28), 7.19--7.14 (m, 2H, H-11 and H-30), 7.00 (d, 1H, *J* = 8.1 Hz, H-12), 6.85 (s, 1H, H-14), 5.68 (s, 2H, H-24), 5.23 (dd, 2H, *J* = 69.0, 12.7 Hz, H-21), 2.83 (dt, 1H, *J* = 13.8, 6.9 Hz, H-15), 2.79--2.68 (m, 2H, H-7), 2.29 (d, 1H, *J* = 12.5 Hz, He-1), 2.21 (dd, 1H, *J* = 12.5, 1.9 Hz, H-5), 1.80--1.45 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.27 (s, 3H, H-19), 1.24 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.20 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.39, 146.75, 145.70, 143.48, 134.61, 134.06, 133.28, 130.49, 130.39, 128.24, 126.89, 124.17, 123.93, 123.89, 123.52, 57.73, 53.85, 47.58, 44.79, 37.91, 36.92, 36.42, 33.46, 29.98, 25.16, 24.00, 23.99, 21.65, 18.53, 16.48; ESI-MS *m/z*: 550.10 (\[M\]^+^). Anal. Calcd for C~30~H~36~BrN~3~O~2~: C 65.45, H 6.59, N 7.63; found C 65.49, H 6.63, N 7.60.

*\[1-(3-bromobenzyl)-1H-1,2,3-triazole-4-yl\]dehydroabietic acid methyl ester* (**3i**): White solid; yield 54.5%; m.p. 146.1--148.0 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+24.59 (c 0.010, CH~2~Cl~2~); IR (KBr, cm^−1^) 2945 (stretching, s, aliphatic C-H), 1716 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.55 (s, 1H, H-23), 7.52 (1H, d, *J* = 7.9 Hz, H-28), 7.44 (s, 1H, H-26), 7.28 (d, 1H, *J* = 9.7 Hz, H-29), 7.21 (d, 1H, *J* = 7.7 Hz, H-30), 7.16 (d, 1H, *J* = 8.2 Hz, H-11), 7.01 (d, 1H, *J* = 8.1 Hz, H-12), 6.86 (s, 1H, H-14), 5.52 (s, 2H, H-24), 5.23 (dd, 2H, *J* = 63.2, 12.7 Hz, H-21), 2.84 (dt, 1H, *J* = 13.8, 6.9 Hz, H-15), 2.77--2.65 (m, 2H, H-7), 2.29 (d, 1H, *J* = 12.7 Hz, He-1), 2.20 (dd, 1H, *J* = 12.5, 1.9 Hz, H-5), 1.86\~1.45 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.27 (s, 3H, H-19), 1.24 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.20 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.46, 146.73, 145.72, 143.82, 136.72, 134.59, 132.01, 130.97, 130.71, 126.91, 126.54, 124.16, 123.94, 123.64, 123.16, 57.70, 53.39, 47.58, 44.82, 37.90, 36.92, 36.39, 33.47, 29.90, 25.15, 23.99, 21.63, 18.52, 16.47; ESI-MS *m/z*: 572.30 (\[M + Na\]^+^). Anal. Calcd for C~30~H~36~BrN~3~O~2~: C 65.45, H 6.59, N 7.63; found C 65.47, H 6.62, N 7.61.

*\[1-(4-bromobenzyl)-1H-1,2,3-triazole-4-yl\]dehydroabietic acid methyl ester* (**3j**): White solid; yield 40.2%; m.p. 172.5--174 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+27.19 (c 0.012, CH~2~Cl~2~); IR (KBr, cm^−1^) 2924 (stretching, s, aliphatic C-H), 1718 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.56--7.50 (m, 3H, H-23, H-27 and H-29), 7.16 (d, 3H, *J* = 8.2 Hz, H-11, H-26 and H-30), 7.01 (d, 1H, *J* = 9.2 Hz, H-12), 6.86 (s, 1H, H-14), 5.50 (s, 2H, H-24), 5.21 (dd, 2H, *J* = 61.3, 12.7 Hz, H-21), 2.84 (dt, *J* = 13.8, 6.9 Hz, 1H, H-15), 2.76--2.67 (m, 2H, H-7), 2.30 (d, 1H, *J* = 12.9 Hz, He-1), 2.19 (dd, 1H, *J* = 12.5, 1.8 Hz, H-5), 1.80\~1.45 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.27 (s, 3H, H-19), 1.25 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.20 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.44, 146.73, 145.77, 143.78, 134.55, 133.55, 132.35, 129.66, 126.91, 124.16, 123.95, 123.52, 123.03, 57.72, 53.48, 47.58, 44.81, 37.89, 36.92, 36.39, 33.47, 29.91, 25.15, 24.00, 21.61, 18.51, 16.47; ESI-MS *m/z*: 572.10 (\[M + Na\]^+^). Anal. Calcd for C~30~H~36~BrN~3~O~2~: C 65.45, H 6.59, N 7.63; found C 65.47, H 6.58, N 7.65.

*\[1-(2-nitrobenzyl)-1H-1,2,3-triazole-4-yl\]dehydroabietic acid methyl ester* (**3k**): White solid; yield 59.8%; m.p. 119.7--122.2 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+28.42 (c 0.016, CH~2~Cl~2~); IR (KBr, cm^−1^) 2929 (stretching, s, aliphatic C-H), 1720 (stretching, s, C=O), 1527 (stretching, s, -NO~2~); ^1^H NMR (600 MHz, CDCl~3~): δ 8.17 (d, 1H, *J* = 7.8 Hz, H-27), 7.76 (1H, s, H-23), 7.61 (t, 1H, *J* = 7.2 Hz, H-29), 7.55 (t, 1H, *J* = 7.5 Hz, H-28), 7.16 (1H, d, *J* = 8.2 Hz, H-11), 7.07 (d, 1H, *J* = 7.7 Hz, H-30), 7.00 (d, 1H, *J* = 8.0 Hz, H-12), 6.85 (1H, s, H-12), 5.95 (s, 2H, H-24), 5.25 (dd, 2H, *J* = 54.6, 12.7 Hz, H-21), 2.82 (1H, m, H-15), 2.77--2.74 (2H, m, H-7), 2.29 (d, 1H, *J* = 12.4 Hz, He-1), 2.22 (dd, 1H, *J =* 12.4, 1.5 Hz, H-5), 1.81--1.44 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.27 (s, 3H, H-19), 1.22 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.20 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.02, 147.12, 146.41, 145.38, 143.35, 134.24, 134.04, 130.24, 129.98, 129.40, 126.56, 125.10, 124.35, 123.84, 123.62, 57.37, 50.52, 47.26, 44.46, 37.57, 36.58, 36.11, 33.12, 29.65, 24.83, 23.66, 21.34, 18.19, 16.16; ESI-MS *m/z*: 514.90 (\[M − H\]^−^). Anal. Calcd for C~30~H~36~N~4~O~4~: C 69.74, H 7.02, N 10.84; found C 69.78, H 7.00, N 10.82.

*\[1-(3-nitrobenzyl)-1H-1,2,3-triazole-4-yl\]dehydroabietic acid methyl ester* (**3l**): White solid; yield 48.3%; m.p. 128.5--132.3 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+6.39 (c 0.011, CH~2~Cl~2~); IR (KBr, cm^−1^) 3074, 2926 (stretching, s, aliphatic C-H), 1712 (stretching, s, C=O), 1533(stretching, s, -NO~2~); ^1^H NMR (600 MHz, CDCl~3~): δ 8.25 (d, 1H, *J* = 7.8 Hz, H-28), 8.19 (s, 1H, H-26), 7.66 (s, 1H, H-23), 7.61 (dt, 2H, *J* = 15.5, 7.7 Hz, H-29 and H-30), 7.17 (d, 1H, *J* = 8.2 Hz, H-11), 7.02 (d, 1H, *J* = 8.2 Hz, H-12), 6.86 (s, 1H, H-14), 5.68 (s, 2H, H-24), 5.24 (dd, 2H, *J* = 47.4, 12.7 Hz, H-21), 2.85 (dt, 1H, *J* = 13.8, 6.9 Hz, H-15), 2.79--2.70 (2H, m, H-7), 2.31 (d, 1H, *J* = 13.0, He-1), 2.21 (dd, 1H, *J* = 12.5, 1.8, H-5), 1.84--1.47(m, 7H, Ha-1, H-2, H-3 and H-6), 1.28 (3H, s, H-19), 1.25 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.21 (3H, s, H-20); ^13^C NMR(150 MHz, CDCl~3~): δ 178.58, 148.70, 146.86, 145.90, 144.15, 136.81, 134.65, 133.98, 130.47, 127.02, 124.30, 124.11, 123.96, 123.94, 122.97, 57.80, 53.23, 47.72, 44.93, 38.02, 37.04, 36.54, 33.59, 30.06, 25.28, 24.12, 18.63, 16.60; ESI-MS *m/z*: 514.90 (\[M − H\]^−^). Anal. Calcd for C~30~H~36~N~4~O~4~: C 69.74, H 7.02, N 10.84; found C 69.75, H 7.01, N 10.85.

*\[1-(4-nitrobenzyl)-1H-1,2,3-triazole-4-yl\]dehydroabietic acid methyl* ester (**3m**): White solid; yield 41.1%; m.p. 173.9--176.7 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+16.44 (c 0.012, CH~2~Cl~2~); IR (KBr, cm^−1^) 2949 (stretching, s, aliphatic C-H), 1716 (stretching, s, C=O), 1530(stretching, s, -NO~2~); ^1^H NMR (600 MHz, CDCl~3~): δ 8.26 (d, 2H, *J* = 8.6 Hz, H-27 and H-29), 7.63 (1H, s, H-23), 7.43 (d, 2H, *J* = 8.5 Hz, H-26 and H-30), 7.18 (d, 1H, *J* = 8.2 Hz, H-11), 7.02 (d, 1H, *J* = 8.1Hz, H-12), 6.86 (1H, s, H-14), 5.68 (s, 2H, H-24), 5.24 (dd, 2H, *J* = 48.4, 12.7 Hz, H-21),2.85 (dt, 1H, *J* = 13.8, 6.9 Hz, H-15), 2.80--2.67 (m, 2H, H-7), 2.31 (d, 1H, *J =* 13.1 Hz, He-1), 2.21 (dd, 1H, *J =* 12.4, 1.4 Hz, H-5), 1.84--1.69 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.28 (s, 3H, H-19), 1.25 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.21 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.58, 148.24, 146.83, 145.99, 144.19, 141.70, 134.59, 128.73, 127.02, 124.47, 124.31,124.14, 124.03, 57.80, 53.24, 47.73, 44.93, 38.01, 37.04, 36.54, 33.58, 30.08, 25.28, 24.11, 21.77, 18.63, 16.61; ESI-MS *m/z*: 514.86 (\[M − H\]^−^). Anal. Calcd for C~30~H~36~N~4~O~4~: C 69.74, H 7.02, N 10.84; found C 69.75, H 7.04, N 10.81.

*\[1-(3-methylbenzyl)-1H-1,2,3-triazole-4-yl\]dehydroabietic acid methyl ester* (**3n**): White solid; yield 51.4%; m.p. 130.7--132.8 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+42.99 (c 0.010, CH~2~Cl~2~); IR (KBr, cm^−1^) 2945 (stretching, s, aliphatic C-H), 1716 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.53 (1H, s, H-23), 7.30 (t, 1H, *J* = 7.6 Hz, H-29), 7.21 (d, 1H, *J* = 7.6 Hz, H-30), 7.17(d, 1H, *J* = 8.2 Hz, H-11), 7.13-.08(m, 2H, H-26 and H-28), 7.02 (d, 1H, *J =* 8.1 Hz, H-12), 6.86 (s, 1H, H-14), 5.51 (s, 2H, H-24), 5.23 (dd, 2H, *J* = 65.3, 12.7 Hz, H-21), 2.85 (dt, 1H, *J* = 13.8, 6.9 Hz, H-15), 2.76--2.67 (m, 2H, H-7), 2.38 (s, 3H, H-31), 2.30 (d, 1H, *J* = 12.6 Hz, He-1), 2.21 (dd, 1H, *J* = 12.4, 1.9 Hz, H-5), 1.80 -1.46 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.28 (s, 3H, H-19), 1.26 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.21 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.57, 146.88, 145.83, 143.64, 139.12, 134.76, 134.55, 129.71, 129.17, 128.92, 127.02, 125.27, 124.30, 124.06, 123.67, 57.89, 54.33, 47.69, 44.94, 38.03, 37.05, 36.49, 33.60, 30.05, 25.29, 24.13, 21.73, 21.49, 18.65, 16.60; ESI-MS *m/z*: 484.8 (\[M − H\]^−^). Anal. Calcd for C~31~H~39~N~3~O~2~: C 76.67, H 8.09, N 8.65; found C 76.66, H 8.05, N 8.62.

*\[1-(4-methylbenzyl)-1H-1,2,3-triazole-4-yl\]dehydroabietic acid methyl ester* (**3o**): White solid; yield 60.1%; m.p. 160.4--162.0 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+28.37 (c 0.013, CH~2~Cl~2~); IR (KBr, cm^−1^) 2927 (stretching, s, aliphatic C-H), 1716 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.49 (s, 1H, H-23), 7.18 (dt, 5H, *J* = 13.3, 8.2 Hz, H-11, H-26, H-27, H-29 and H-30), 7.01 (dd, 1H, *J* = 8.1, 1.2 Hz, H-12), 6.86 (s, 1H, H-14), 5.50 (s, 2H, H-24), 5.20 (dd, 2H, *J* = 66.5, 12.7 Hz, H-21), 2.84 (dt, 1H, *J* = 13.8, 6.9 Hz, H-15), 2.77--2.65 (m, 2H, H-7), 2.38 (s, 3H, H-31), 2.29 (d, 1H, *J* = 12.8 Hz, He-1), 2.19 (dd, 1H, *J* = 12.5, 1.8 Hz, H-5), 1.84--1.46 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.26 (s, 3H, H-19), 1.25 (d, 6H, *J* = 6.9 Hz, H-16 and H-17), 1.23 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.42, 146.76, 145.70, 143.47, 138.75, 134.64, 131.48, 129.81, 128.12, 126.88, 124.17, 123.92, 123.40, 57.76, 54.00, 47.56, 44.81, 37.90, 36.92, 36.37, 33.47, 29.93, 25.16, 24.00, 21.60, 21.19, 18.52, 16.47; ESI-MS *m/z*: 508.10 (\[M + Na\]^+^). Anal. Calcd for C~31~H~39~N~3~O~2~: C 76.67, H 8.09, N 8.65; found C 76.67, H 8.06, N 8.68.

*\[1-(3-methoxybenzyl)-1H-1,2,3-triazole-4-yl\]dehydroabietic acid methyl ester* (**3p**): Brown solid; yield 41.3%; m.p. 106.5--108.0 °C; $\left\lbrack \alpha \right\rbrack_{D}^{20}$+9.55 (c 0.012, CH~2~Cl~2~); IR (KBr, cm^−1^) 2929 (stretching, s, aliphatic C-H), 1712 (stretching, s, C=O); ^1^H NMR (600 MHz, CDCl~3~): δ 7.54 (s, 1H, H-23), 7.30 (t, 1H, *J* = 7.8 Hz and H-5), 7.16 (d, 1H, *J* = 8.2 Hz, H-11), 7.00 (d, 1H, *J =* 8.1, H-12), 6.91 (dd, 1H, *J* = 8.2, 2.2 Hz, H-28), 6.86 (m, 2H, H-14 and H-30), 6.81 (s, 1H, H-26), 5.51 (s, 2H, H-24), 5.21 (dd, 2H, *J* = 68.9, 12.7 Hz, H-21), 3.80 (s, 3H, H-31), 2.84 (dt, 1H, *J* = 13.8, 6.9 Hz, H-15), 2.75--2.71 (m, 2H, H-7), 2.29 (d, 1H, *J* = 12.5 Hz, He-1), 2.19 (dd, 1H, *J =* 12.4, 1.5 Hz, H-5), 1.90\~1.46 (m, 7H, Ha-1, H-2, H-3 and H-6), 1.26 (s, 3H, H-19), 1.24 (d, 6H, *J =* 6.9 Hz, H-16 and H-17), 1.19 (s, 3H, H-20); ^13^C NMR (150 MHz, CDCl~3~): δ 178.57, 159.81, 146.41, 145.35, 143.22, 135.66, 134.30, 129.90, 126.57, 123.83, 123.59, 123.26, 119.88, 113.94, 113.32, 57.41, 54.96, 53.77, 47.22, 44.50, 37.58, 36.59, 36.04, 33.14, 29.58, 24.84, 23.68, 21.28, 18.19, 16.15; ESI-MS *m/z*: 523.30 (\[M + Na\]^+^). Anal. Calcd for C~31~H~39~N~3~O~3~: C 74.22, H 7.84, N 8.38; found C 74.20, H 7.85, N 8.40.

3.4. In Vitro Antiproliferative Evaluation {#sec3dot4-molecules-24-04191}
------------------------------------------

All the compounds (**3a**--**p**) were evaluated for their in vitro cytotoxicity against the following human cancer cell lines including CNE-2, HepG2, BEL-7402, Hela and normal liver cell HL-7702 by MTT assay. The cell lines were plated in 96-well plates at density of 5×10^3^ cells/well and maintained at 37 °C with 5% CO~2~. The target compounds **3a**--**p** dissolved in DMSO and further dilutions were made with DMEM, with cisplatin as the positive control. The concentration of the compounds used were 0.8, 4, 20, 100 μM. After the treatment of another 48 h and 72 h with different concentration of the samples (0.8, 4, 20, 100 μM), Therewith, 20 μL of MTT (5 mg/mL) was added and incubated for about 4 h. The medium was thrown away and the purple formazan precipitations were dissolved in 150 μL DMSO. The O. D. Value was measured at 490 nm in an enzyme labeling instrument \[[@B36-molecules-24-04191],[@B37-molecules-24-04191]\].

4. Conclusions {#sec4-molecules-24-04191}
==============

Taken together, a series of dehydroabietic acid coupled 1,2,3-triazole derivatives (**3a**--**p**) were synthesized by a convenient one-pot Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction from propynyl ester **2** and a variety of readily available benzyl chloride/bromide without isolation of potentially unstable organic azide. The synthesized compounds were screened for cytotoxic activity against a panel of four human cancer cell lines and the human HL-7702 normal cell line using an MTT assay. Some compounds exhibited better anticancer activity against the tested cancer cell lines compared to positive controls cisplatin and low cytotoxicity on human normal liver cell HL-7702. Among these compounds, compounds **3c** (IC~50~ = 5.90 ± 0.41 µM) and **3k** (IC~50~ = 6.25 ± 0.37 μM) were the most promising derivatives. The antitumor activity in vivo and the mechanism in antitumor activity of dehydroabietic acid-1,2,3-triazole hybrids are under investigation.

**Sample Availability:** Samples of the compounds **2** and **3a**--**p** are available from the authors.

The Supplementary Materials are available online.
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![Synthesis of dehydroabietic acid-1,2,3-triazole hybrids. *Reagents and conditions*: (i) propargyl bromide, anhydrous potassium carbonate, DMF, RT, 4 h, yield 86.3%; (ii) benzyl chloride/bromide, NaN~3~, CuI, DMF/H~2~O, RT, 5 h, yield 40.2--60.4%.](molecules-24-04191-sch001){#molecules-24-04191-sch001}
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###### 

Antiproliferative activity of dehydroabietic acid-based 1,2,3-triazole compounds ^a^.

  Compound                  IC~50~ (μM)                                                 
  ------------------------- -------------- -------------- -------------- -------------- --------------
  **3a** (R = H)            33.40 ± 0.33   \>100          36.44 ± 070    67.88 ± 0.56   \>100
  **3b** (R = *o*-F)        21.44 ± 0.52   25.86 ± 0.27   18.63 ± 0.82   17.76 ± 0.31   \>100
  **3c** (R = *m*-F)        10.92 ± 0.21   5.90 ± 0.41    16.72 ± 0.06   20.05 ± 0.54   \>100
  **3d** (R = *p*-F)        12.20 ± 0.33   20.60 ± 0.09   14.84 ± 075    22.33 ± 0.35   \>100
  **3e** (R = *o*-Cl)       74.88 ± 0.14   45.08 ± 0.33   25.06 ± 0.32   44.28 ± 0.43   \>100
  **3f** (R = *m*-Cl)       59.03 ± 0.28   22.27 ± 0.35   26.09 ± 0.15   53.78 ± 0.32   \>100
  **3g** (R = *p*-Cl)       60.73 ± 066    \>100          38.04 ± 0.48   \>100          \>100
  **3h** (R = *o*-Br)       48.30 ± 0.27   35.42 ± 0.21   27.26 ± 0.36   25.90 ± 0.20   \>100
  **3i** (R = *m*-Br)       44.14 ± 0.22   40.66 ± 0.62   36.88 ± 0.23   56.08 ± 0.36   \>100
  **3j** (R = *p*-Br)       \>100          23.40 ± 0.32   14.53 ± 0.62   43.18 ± 0.22   \>100
  **3k** (R = *o*-NO~2~)    44.90 ± 0.32   6.25 ± 0.37    18.62 ± 0.26   \>100          \>100
  **3l** (R = *m*-NO~2~)    11.45 ± 0.18   15.83 ± 0.64   15.39 ± 0.51   67.37 ± 0.33   \>100
  **3m** (R = *p*-NO~2~)    19.61 ± 0.38   \>100          22.81 ± 0.22   22.48 ± 0.35   \>100
  **3n** (R = *m*-CH~3~)    \>100          60.18 ± 0.39   23.61 ± 0.44   25.32 ± 0.81   \>100
  **3o** (R = *p*-CH~3~)    \>100          51.78 ± 0.43   41.89 ± 0.72   42.51 ± 0.37   \>100
  **3p** (R = *m*-OCH~3)~   80.98 ± 0.78   \>100          25.03 ± 0.22   24.66 ± 0.16   \>100
  DHAA                      88.64 ± 0.73   80.36 ± 0.84   46.70 ± 0.55   37.40 ± 0.64   \>100
  Cisplatin                 8.75 ± 0.24    6.42 ± 0.18    12.68 ± 0.33   1.94 ± 0.20    20.76 ± 0.83

^a^ IC~50~ values are expressed as the mean ± SD (standard deviation) from three independent experiments. The results indicate statistically significant differences at *p* \< 0.05.
